1. PouponR, ChazouilleresO, BalkauB, et al.Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA‐PBC Group. J Hepatol1999;30:408. CrossRef

2. CulpKS, FlemingCR, DuffyJ, et al.Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc1982;57:365.

3. GershwinME, MackayIR, SturgessA, et al.Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol1987;138:3525.

4. GershwinME, RowleyM, DavisPA, et al.Molecular biology of the 2‐oxo‐acid dehydrogenase complexes and anti‐mitochondrial antibodies. Prog Liver Dis1992;10:47.

5. KramsSM, SurhCD, CoppelRL, et al.Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. Hepatology1989;9:411. CrossRef

6. LeungPS, YangGX, DhirapongA, et al.Animal models of primary biliary cirrhosis: materials and methods. Methods Mol Biol2012;900:291. CrossRef

7. JoplinR, LindsayJG, HubscherSG, et al.Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study. Hepatology1991;14:442. CrossRef

8. OdinJA, HuebertRC, Casciola‐RosenL, et al.Bcl‐2‐dependent oxidation of pyruvate dehydrogenase‐E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest2001;108:223. CrossRef

9. SelmiC, BalkwillDL, InvernizziP, et al.Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic‐metabolizing bacterium. Hepatology2003;38:1250. CrossRef

10. StemerowiczR, HopfU, MollerB, et al.Are antimitochondrial antibodies in primary biliary cirrhosis induced by R(rough)‐mutants of enterobacteriaceae?Lancet1988;2:1166. CrossRef

11. HopfU, MollerB, StemerowiczR, et al.Relation between Escherichia coli R(rough)‐forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet1989;2:1419. CrossRef

12. ButlerP, ValleF, Hamilton‐MillerJM, et al.M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol1993;17:408. CrossRef

13. LongSA, QuanC, Van de WaterJ, et al.Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol2001;167:2956. CrossRef

14. LeungPS, QuanC, ParkO, et al.Immunization with a xenobiotic 6‐bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol2003;170:5326. CrossRef

15. OhbaK, OmagariK, KinoshitaH, et al.Primary biliary cirrhosis among atomic bomb survivors in Nagasaki, Japan. J Clin Epidemiol2001;54:845. CrossRef

16. GershwinME, SelmiC, WormanHJ, et al.Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview‐based study of 1032 patients. Hepatology2005;42:1194. CrossRef

17. PrinceMI, DuckerSJ, JamesOF. Case‐control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut2010;59:508. CrossRef

18. ZeinCO, BeattyK, PostAB, et al.Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment. Hepatology2006;44:1564. CrossRef

19. PrinceMI, ChetwyndA, DiggleP, et al.The geographical distribution of primary biliary cirrhosis in a well‐defined cohort. Hepatology2001;34:1083. CrossRef

20. WatsonRG, AngusPW, DewarM, et al.Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. Gut1995;36:927. CrossRef

21. Witt‐SullivanH, HeathcoteJ, CauchK, et al.The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology1990;12:98. CrossRef

22. Parikh‐PatelA, GoldE, MackayIR, et al.The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases. Clin Immunol1999;91:206. CrossRef

23. HowelD, FischbacherCM, BhopalRS, et al.An exploratory population‐based case‐control study of primary biliary cirrhosis. Hepatology2000;31:1055. CrossRef

24. SelmiC, MayoMJ, BachN, et al.Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology2004;127:485. CrossRef

25. FeiziT, NaccaratoR, SherlockS, et al.Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clin Exp Immunol1972;10:609.

26. NeubergerJ. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol2003;39:142. CrossRef

27. LiuX, InvernizziP, LuY, et al.Genome‐wide meta‐analyses identify three loci associated with primary biliary cirrhosis. Nat Genet2010;42:658. CrossRef

28. JacksonH, Solaymani‐DodaranM, CardTR, et al.Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population‐based cohort study. Hepatology2007;46:1131. CrossRef

29. KramsSM, Van de WaterJ, CoppelRL, et al.Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis. Hepatology1990;12:306. CrossRef

30. HirschfieldGM, LiuX, XuC, et al.Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med2009;360:2544. CrossRef

31. KongF, LiJX, LiP, et al.Association of TNFSF4 polymorphisms with susceptibility to primary Sjogren's syndrome and primary biliary cirrhosis in a Chinese Han population. Clin Exp Rheumatol2013;31:546.

32. MarucciL, UgiliL, MacarriG, et al.Primary biliary cirrhosis: modalities of injury and death in biliary epithelium. Dig Liver Dis2001;33:576. CrossRef

33. SherlockS, ScheuerPJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med1973;289:674. CrossRef

34. JamesO, MacklonAF, WatsonAJ. Primary biliary cirrhosis–a revised clinical spectrum. Lancet1981;1:1278.

35. PrinceMI, ChetwyndA, CraigWL, et al.Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut2004;53:865. CrossRef

36. CroweJ, ChristensenE, DoniachD, et al.Early features of primary biliary cirrhosis: an analysis of 85 patients. Am J Gastroenterol1985;80:466.

37. HeathcoteJ. The clinical expression of primary biliary cirrhosis. Semin Liver Dis1997;17:23. CrossRef

38. HeathcoteEJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology2000;31:1005. CrossRef

39. NewtonJL, HudsonM, TachtatzisP, et al.Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. Hepatology2007;45:1496. CrossRef

40. JonesEA, BergasaNV. The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol1999;11:623. CrossRef

41. BergasaNV, ThomasDA, VergallaJ, et al.Plasma from patients with the pruritus of cholestasis induces opioid receptor‐mediated scratching in monkeys. Life Sci1993;53:1253. CrossRef

42. LaurinJM, DeSotelCK, JorgensenRA, et al.The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol1994;89:1840.

43. Del PuppoM, KienleMG, PetroniML, et al.Serum 27‐hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. J Lipid Res1998;39:2477.

44. EpsteinO, ArborghB, SagivM, et al.Is copper hepatotoxic in primary biliary cirrhosis?J Clin Pathol1981;34:1071. CrossRef

45. ZurgilN, BakimerR, KaplanM, et al.Anti‐pyruvate dehydrogenase autoantibodies in primary biliary cirrhosis. J Clin Immunol1991;11:239. CrossRef

46. DahnrichC, ParesA, CaballeriaL, et al.New ELISA for detecting primary biliary cirrhosis‐specific antimitochondrial antibodies. Clin Chem2009;55:978. CrossRef

47. SzosteckiC, GuldnerHH, WillH. Autoantibodies against “nuclear dots” in primary biliary cirrhosis. Semin Liver Dis1997;17:71. CrossRef

48. WichmannI, Montes‐CanoMA, RespaldizaN, et al.Clinical significance of anti‐multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol2003;38:996. CrossRef

49. BogdanosDP, VerganiD, MuratoriP, et al.Specificity of anti‐sp100 antibody for primary biliary cirrhosis. Scand J Gastroenterol2004;39:405; author reply 7. CrossRef

50. ZuchnerD, SternsdorfT, SzosteckiC, et al.Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology1997;26:1123.

51. CorpechotC, CarratF, Poujol‐RobertA, et al.Noninvasive elastography‐based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology2012;56:198. CrossRef

52. ModenaV, MarengoC, AmorosoA, et al.Primary biliary cirrhosis and rheumatic diseases: a clinical, immunological and immunogenetical study. Clin Exp Rheumatol1986;4:129.

53. FeiziT. Immunoglobulins in chronic liver disease. Gut1968;9:193. CrossRef

54. BergPA, KleinR. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis1992;10:85. CrossRef

55. CzajaAJ, CarpenterHA, MannsMP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology1993;105:1522. CrossRef

56. MunozLE, ThomasHC, ScheuerPJ, et al.Is mitochondrial antibody diagnostic of primary biliary cirrhosis?Gut1981;22:136. CrossRef

57. LeungPS, RossaroL, DavisPA, et al.Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology2007;46:1436. CrossRef

58. MetcalfJV, MitchisonHC, PalmerJM, et al.Natural history of early primary biliary cirrhosis. Lancet1996;348:1399. CrossRef

59. AssassiS, FritzlerMJ, ArnettFC, et al.Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol2009;36:2250. CrossRef

60. LudwigJ, DicksonER, McDonaldGS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol1978;379:103. CrossRef

61. ScheuerP. Primary biliary cirrhosis. Proc R Soc Med1967;60:1257.

62. GoldinRD. Diagnosis of biliary ductopaenia. Histopathology1997;31:397. CrossRef

63. JainS, ScheuerPJ, ArcherB, et al.Histological demonstration of copper and copper‐associated protein in chronic liver diseases. J Clin Pathol1978;31:784. CrossRef

64. ZeinCO, AnguloP, LindorKD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?Clin Gastroenterol Hepatol2003;1:89. CrossRef

65. WongRK, LimSG, WeeA, et al.Primary biliary cirrhosis in Singapore: evaluation of demography, prognostic factors and natural course in a multi‐ethnic population. J Gastroenterol Hepatol2008;23:599. CrossRef

66. LindorKD, GershwinME, PouponR, et al.Primary biliary cirrhosis. Hepatology2009;50:291. CrossRef

67. TsujiK, WatanabeY, Van De WaterJ, et al.Familial primary biliary cirrhosis in Hiroshima. J Autoimmun1999;13:171. CrossRef

68. KarSP, SeldinMF, ChenW, et al.Pathway‐based analysis of primary biliary cirrhosis genome‐wide association studies. Genes Immun2013;14:179. CrossRef

69. RobsonSC, HiftRJ, KirschRE. Primary biliary cirrhosis. A retrospective survey at Groote Schuur Hospital, Cape Town. S Afr Med J1990;78:19.

70. LuceyMR, NeubergerJM, WilliamsR. Primary biliary cirrhosis in men. Gut1986;27:1373. CrossRef

71. AnandAC, EliasE, NeubergerJM. End‐stage primary biliary cirrhosis in a first generation migrant south Asian population. Eur J Gastroenterol Hepatol1996;8:663. CrossRef

72. Al‐HarthyN, KumagiT, ColtescuC, et al.The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology2010;52:562. CrossRef

73. ZukowskiTH, JorgensenRA, DicksonER, et al.Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy. Am J Gastroenterol1998;93:958. CrossRef

74. ParesA, BrugueraM, RodesJ. Renal tubular damage depresses renal uric acid excretion in primary biliary cirrhosis. Hepatology1984;4:1265.

75. PowellFC, SchroeterAL, DicksonER. Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med1987;62:75.

76. MillsP, MacSweenRN, WatkinsonG. Arthritis and primary biliary cirrhosis. Br Med J1977;2:1224. CrossRef

77. MillsPR, VallanceR, BirnieG, et al.A prospective survey of radiological bone and joint changes in primary biliary cirrhosis. Clin Radiol1981;32:297. CrossRef

78. EsquivelCO, Van ThielDH, DemetrisAJ, et al.Transplantation for primary biliary cirrhosis. Gastroenterology1988;94:1207.

79. PereiraSP, BrayGP, PittPI, et al.Non‐invasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol1999;11:323. CrossRef

80. HodgsonSF, DicksonER, EastellR, et al.Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone1993;14:819. CrossRef

81. KrowkaMJ, GrambschPM, EdellES, et al.Primary biliary cirrhosis: relation between hepatic function and pulmonary function in patients who never smoked. Hepatology1991;13:1095. CrossRef

82. KeeffeEB. Sarcoidosis and primary biliary cirrhosis. Literature review and illustrative case. Am J Med1987;83:977. CrossRef

83. YapSH, SchillingsPH, Van TongerenJH. Acute interstitial pneumonia (fibrosing alveolitis) in a patient with primary biliary cirrhosis. Neth J Med1980;23:111.

84. StrobelES, BonnetRB, WernerP, et al.Bronchiolitis obliterans organising pneumonia and primary biliary cirrhosis‐like lung involvement in a patient with primary biliary cirrhosis. Clin Rheumatol1998;17:246. CrossRef

85. ButlerP, Hamilton‐MillerJM, McIntyreN, et al.Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups. Gut1995;36:931. CrossRef

86. IslamS, RiordanJW, McDonaldJA. Case report: a rare association of primary biliary cirrhosis and systemic lupus erythematosus and review of the literature. J Gastroenterol Hepatol1999;14:431. CrossRef

87. GagnerieF, TaillanB, Euller‐ZieglerL, et al.Primary biliary cirrhosis, temporal arteritis (giant cell arteritis) and polymyalgia rheumatica in a single patient. Scand J Rheumatol1988;17:231. CrossRef

88. RaiGS, HamlynAN, DahlMG, et al.Primary biliary cirrhosis, cutaneous capillaritis, and IgM‐associated membranous glomerulonephritis. Br Med J1977;1:817. CrossRef

89. TsaiWC, MatsumuraK, SonooM, et al.[Dystrophin abnormality in a patient with polymyositis associated with primary biliary cirrhosis and myocardial injury]. Rinsho Shinkeigaku1996;36:876.

90. DickeyW, McMillanSA, CallenderME. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J Clin Gastroenterol1997;25:328. CrossRef

91. SjobergK, LindgrenS, ErikssonS. Frequent occurrence of non‐specific gliadin antibodies in chronic liver disease. Endomysial but not gliadin antibodies predict coeliac disease in patients with chronic liver disease. Scand J Gastroenterol1997;32:1162. CrossRef

92. LofgrenJ, JarnerotG, DanielssonD, et al.Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol1985;20:647. CrossRef

93. NijhawanPK, TherneauTM, DicksonER, et al.Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology1999;29:1396. CrossRef

94. HowelD, MetcalfJV, GrayJ, et al.Cancer risk in primary biliary cirrhosis: a study in northern England. Gut1999;45:756. CrossRef

95. WeeA, LudwigJ. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?Ann Intern Med1985;102:581. CrossRef

96. LudwigJ, BattsKP(eds). Practical Liver Biopsy Interpretation, 2nd edn. Chicago: American Society of Clinical Pathologists; 1998.

97. ChiaSC, BergasaNV, KleinerDE, et al.Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci1998;43:2177. CrossRef

98. ZimmermanHJ. Hepatotoxicity, 2nd edn. Philadelphia: Lippincott Williams & Wilkins; 1999.

99. AlvarezF, BergPA, BianchiFB, et al.International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol1999;31:929. CrossRef

100. HennesEM, ZeniyaM, CzajaAJ, et al.Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology2008;48:169. CrossRef

101. ChazouilleresO, WendumD, SerfatyL, et al.Primary biliary cirrhosis‐autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology1998;28:296. CrossRef

102. InvernizziP, CrosignaniA, BattezzatiPM, et al.Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis. Hepatology1997;25:1090. CrossRef

103. KimWR, PoteruchaJJ, JorgensenRA, et al.Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology1997;26:22. CrossRef

104. GisbertJP, JonesEA, PajaresJM, et al.Review article: is there an optimal therapeutic regimen for antimitochondrial antibody‐negative primary biliary cirrhosis (autoimmune cholangitis). Aliment Pharmacol Ther2003;17:17. CrossRef

105. TsuneyamaK, Van De WaterJ, Van ThielD, et al.Abnormal expression of PDC‐E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody‐negative primary biliary cirrhosis. Hepatology1995;22:1440.

106. MayoMJ, LipskyPE, MillerSN, et al.Similar T‐cell oligoclonality in antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis. Dig Dis Sci2001;46:345. CrossRef

107. KrzeskiP, ZychW, KraszewskaE, et al.Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?Hepatology1999;30:865. CrossRef

108. MahlTC, ShockcorW, BoyerJL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol1994;20:707. CrossRef

109. PrinceM, ChetwyndA, NewmanW, et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow‐up for up to 28 years. Gastroenterology2002;123:1044. CrossRef

110. DicksonER, GrambschPM, FlemingTR, et al.Prognosis in primary biliary cirrhosis: model for decision making. Hepatology1989;10:1. CrossRef

111. ChristensenE, AltmanDG, NeubergerJ, et al.Updating prognosis in primary biliary cirrhosis using a time‐dependent Cox regression model. PBC1 and PBC2 trial groups. Gastroenterology1993;105:1865.

112. ShapiroJM, SmithH, SchaffnerF. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut1979;20:137. CrossRef

113. JonesEA, BergasaNV. The pruritus of cholestasis. Hepatology1999;29:1003. CrossRef

114. HeathcoteEJ, Cauch‐DudekK, WalkerV, et al.The Canadian multicenter double‐blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology1994;19:1149. CrossRef

115. PouponRE, PouponR, BalkauB. Ursodiol for the long‐term treatment of primary biliary cirrhosis. The UDCA‐PBC Study Group. N Engl J Med1994;330:1342. CrossRef

116. LeuschnerU. Primary biliary cirrhosis–presentation and diagnosis. Clin Liver Dis2003;7:741. CrossRef

117. TraunerM, GraziadeiIW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther1999;13:979. CrossRef

118. LindorKD, DicksonER, BaldusWP, et al.Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology1994;106:1284.

119. CombesB, CarithersRLJr, MaddreyWC, et al.A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology1995;22:759.

120. ParesA, CaballeriaL, RodesJ, et al.Long‐term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double‐blind controlled multicentric trial. UDCA‐Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol2000;32:561. CrossRef

121. PouponRE, LindorKD, Cauch‐DudekK, et al.Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology1997;113:884. CrossRef

122. GoulisJ, LeandroG, BurroughsAK. Randomised controlled trials of ursodeoxycholic‐acid therapy for primary biliary cirrhosis: a meta‐analysis. Lancet1999;354:1053. CrossRef

123. GluudC, ChristensenE. Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?J Hepatol2001;34:787. CrossRef

124. PapatheodoridisGV, HadziyannisES, DeutschM, et al.Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12‐year, prospective, randomized, controlled trial. Am J Gastroenterol2002;97:2063. CrossRef

125. CorpechotC, CarratF, PouponR, et al.Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol‐treated patients. Gastroenterology2002;122:652. CrossRef

126. CorpechotC, CarratF, BahrA, et al.The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology2005;128:297. CrossRef

127. ParesA, CaballeriaL, RodesJ. Excellent long‐term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology2006;130:715. CrossRef

128. CorpechotC, AbenavoliL, RabahiN, et al.Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis. Hepatology2008;48:871. CrossRef

129. RautiainenH, KarkkainenP, KarvonenAL, et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three‐year randomized trial. Hepatology2005;41:747. CrossRef

130. HoofnagleJH, DavisGL, SchaferDF, et al.Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology1986;91:1327.

131. BodenheimerHCJr, SchaffnerF, SternliebI, et al.A prospective clinical trial of D‐penicillamine in the treatment of primary biliary cirrhosis. Hepatology1985;5:1139. CrossRef

132. DicksonER, FlemingTR, WiesnerRH, et al.Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med1985;312:1011. CrossRef

133. NeubergerJ, ChristensenE, PortmannB, et al.Double blind controlled trial of d‐penicillamine in patients with primary biliary cirrhosis. Gut1985;26:114. CrossRef

134. LombardM, PortmannB, NeubergerJ, et al.Cyclosporin A treatment in primary biliary cirrhosis: results of a long‐term placebo controlled trial. Gastroenterology1993;104:519.

135. ChristensenE, NeubergerJ, CroweJ, et al.Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology1985;89:1084.

136. HeathcoteJ, RossA, SherlockS. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology1976;70:656.

137. KaplanMM, AllingDW, ZimmermanHJ, et al.A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med1986;315:1448. CrossRef

138. WarnesTW, SmithA, LeeFI, et al.A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol1987;5:1. CrossRef

139. BodenheimerHJr, SchaffnerF, PezzulloJ. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology1988;95:124.

140. GongY, GluudC. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev2004;(2):CD004481.

141. CombesB, EmersonSS, FlyeNL, et al.Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology2005;42:1184. CrossRef

142. TalwalkarJA, AnguloP, KeachJC, et al.Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol2005;39:168. CrossRef

143. AnguloP, PatelT, JorgensenRA, et al.Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology2000;32:897. CrossRef

144. MitchisonHC, PalmerJM, BassendineMF, et al.A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three‐year results. J Hepatol1992;15:336. CrossRef

145. AnguloP, JorgensenRA, KeachJC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology2000;31:318. CrossRef

146. LeuschnerM, MaierKP, SchlichtingJ, et al.Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double‐blind trial. Gastroenterology1999;117:918. CrossRef

147. TraunerMI, HalilbasicE, Kazemi‐ShiraziL, et al.Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. Dig Dis2014;32:631. CrossRef

148. LevyC, PeterJA, NelsonDR, et al.Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther2011;33:235. CrossRef

149. SylvestrePB, BattsKP, BurgartLJ, et al.Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl2003;9:1086. CrossRef

150. GhentCN, CarruthersSG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double‐blind, crossover, randomized trial. Gastroenterology1988;94:488.

151. PodestaA, LopezP, TergR, et al.Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci1991;36:216. CrossRef

152. BachsL, ParesA, ElenaM, et al.Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet1989;1:574. CrossRef

153. MayoMJ, HandemI, SaldanaS, et al.Sertraline as a first‐line treatment for cholestatic pruritus. Hepatology2007;45:666. CrossRef

154. SchworerH, HartmannH, RamadoriG. Relief of cholestatic pruritus by a novel class of drugs: 5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists: effectiveness of ondansetron. Pain1995;61:33. CrossRef

155. O'DonohueJW, PereiraSP, AshdownAC, et al.A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther2005;21:1041. CrossRef

156. ThealJJ, ToosiMN, GirlanL, et al.A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology2005;41:1305. CrossRef

157. PrinceMI, MitchisonHC, AshleyD, et al.Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo‐controlled, cross‐over trial. Aliment Pharmacol Ther2003;17:137. CrossRef

158. ter BorgPC, van OsE, van den BroekWW, et al.Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol2004;4:13. CrossRef

159. RongG, ZhouY, XiongY, et al.Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol2009;156:217. CrossRef

160. MenonKV, AnguloP, BoeGM, et al.Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol2003;98:889. CrossRef

161. LevyC, HarnoisDM, AnguloP, et al.Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int2005;25:117. CrossRef

162. GuanabensN, ParesA, RosI, et al.Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol2003;98:2268. CrossRef

163. ZeinCO, JorgensenRA, ClarkeB, et al.Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo‐controlled trial. Hepatology2005;42:762. CrossRef

164. GuanabensN, ParesA, del RioL, et al.Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol1992;15:345. CrossRef

165. CrippinJS, LindorKD, JorgensenR, et al.Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?Hepatology1992;15:858. CrossRef

166. Van DamGM, GipsCH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol1997;32:77. CrossRef

167. SchaffnerF. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology1969;57:253.

168. KuriharaT, AkimotoM, AbeK, et al.Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther1993;15:890.

169. RitzelU, LeonhardtU, NatherM, et al.Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol2002;36:454. CrossRef

170. KojimaS, ToyotaY, ShibaM, et al.Different apheresis methods in the treatment of hypercholesterolemia in primary biliary cirrhosis: a case report. Artif Organs1995;19:938. CrossRef

171. JoshiS, Cauch‐DudekK, WanlessIR, et al.Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology2002;35:409. CrossRef

172. GunsarF, AkarcaUS, ErsozG, et al.Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis‐autoimmune hepatitis overlap syndrome. Hepatogastroenterology2002;49:1195.